Nykob (Olanzapine)

Olanzapine, the active ingredient in Nykob, is an atypical antipsychotic presented as a 10 mg tablet for oral use. It treats schizophrenia and bipolar I disorder in adults and adolescents. GNH USA supplies Nykob as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Nykob as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is an atypical antipsychotic used in the management of several psychiatric disorders.

- Schizophrenia: reduces psychotic symptoms such as delusions and hallucinations. - Bipolar I disorder (manic phase): controls acute manic episodes and helps maintain mood stability. - Schizoaffective disorder: alleviates both psychotic and mood components of the condition. - Maintenance therapy: helps prevent relapse of psychotic symptoms after stabilization.

Olanzapine may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Weight gain: increased appetite and caloric intake. - Sedation: drowsiness or feeling of being unusually tired. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Elevated triglycerides: rise in blood lipid levels. - Orthostatic hypotension: drop in blood pressure upon standing.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: rare but potentially life‑threatening reaction. - Hyperglycaemia and new‑onset diabetes mellitus. - Tardive dyskinesia: persistent involuntary movements. - Seizures: increased risk in susceptible individuals. - Severe neutropenia: marked reduction in white‑blood cell count. - Hepatotoxicity: liver enzyme elevations or injury.

When prescribing olanzapine, clinicians should consider several safety aspects.

- Metabolic monitoring: regularly assess weight, glucose, and lipid profiles. - Cardiovascular assessment: monitor blood pressure and heart rate, especially during initiation. - CNS effects: advise patients about sedation and avoid operating heavy machinery. - Pregnancy and lactation: evaluate risk‑benefit ratio; use only if clearly needed. - Elderly with dementia: increased risk of mortality; avoid unless essential. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olanzapine interacts with several drug classes that can alter its effectiveness or safety profile.

Major Interactions (Avoid): - CYP1A2 inhibitors (e.g., fluvoxamine): may increase olanzapine plasma levels. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol): olanzapine may affect their metabolism. - Anticholinergic agents: may exacerbate dry mouth and constipation. - Smoking: induces CYP1A2, potentially lowering olanzine ?  - Antihistamines: may increase sedation. - Lithium: combined use may heighten neuro‑excitatory ?